ICON & Regeneron recognised for demonstrating successful
collaboration between pharma & CRO
DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ: ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, and Regeneron Pharmaceuticals, Inc., a leading
science-based biopharmaceutical company that discovers, invents,
develops, manufactures and commercializes medicines for the treatment of
serious medical conditions, have won the Partnership in Clinical
Research award at the 2017
PharmaTimes International Clinical Researcher of the Year Awards,
which took place in London on 18th May. The companies were
represented by Agnieszka Szpineta of ICON and Jacquie Kuritzky of
Regeneron.
Designed to challenge, recognise and reward the talent and passion of
industry and academic researchers, the PharmaTimes International
Clinical Researcher of the Year Awards is the only global competition
that tests the competencies and skills of clinical research
professionals in a real-life challenge against their peers. Entrants in
2017 came from 48 different countries and were subject to a rigorous
3-step entry process, judged by a panel of senior industry leaders. With
a co-operation that started in 2010, the project management
professionals from ICON and Regeneron were judged to have demonstrated
the best skills and collaborative qualities for successful partnerships.
The Partnership in Clinical Research Award is the second PharmaTimes
award that ICON has won in 2017. In April, two
ICON CRAs won awards in the US Clinical Researcher of the Year
competition.
Commenting on the award, ICON Chief Executive Officer, Dr. Steve Cutler,
said: "We are very proud to receive further industry recognition for
having the best skills, expertise and collaborative qualities that drive
successful clinical research partnerships. We work hard to ensure the
continuous development of our people and in promoting a culture that is
based on teamwork, trust and a commitment to helping our customers solve
complex development challenges. We look forward to continuing our
partnership with Regeneron and to helping them bring to market medicines
that will improve the lives of patients with cancer, chronic pain,
cardiovascular disease and skin disorders. "
Bari Kowal, Head of Global Clinical Operations at Regeneron, stated,
"Regeneron is pleased to receive this recognition together with ICON. As
a science-driven biotechnology company, Regeneron has been dedicated and
passionate for nearly 30 years to cultivate an innovative and
collaborative approach to drug development. We maintain a priority and
commitment to preserving an environment that empowers people to feel
invested and proud of what we are hoping to accomplish. Our
collaboration with ICON has been extremely successful to date and
represents an exciting synergy to turn ground breaking science into
medicines that have the potential to bring new hope to patients with a
range of serious diseases."
A full list of ICON's industry awards can be viewed at www.iconplc.com/awards
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 87 locations in 38 countries and
has approximately 12,300 employees. Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON/ICLR-G
View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005077/en/
ICON Media Contact
Camille Frederix
Weber Shandwick
Tel:
+44 (0)207 067 0272
Email: cfrederix@webershandwick.com
Source: ICON plc
News Provided by Acquire Media
